Avandia Meta-Analysis Problems Metastasize For FDA After JAMA Studies
Executive Summary
GlaxoSmithKline's Avandia (rosiglitazone) has become the chorus line to discussions of FDA's drug approval and oversight systems
You may also be interested in...
Adverse Event Surveillance Pilot From AHRQ Examines Hypertension, Diabetes
A study recently initiated by the Agency for Healthcare Research and Quality will develop a distributed network prototype by aggregating medical records and claims data for diabetes and hypertension therapy
Adverse Event Surveillance Pilot From AHRQ Examines Hypertension, Diabetes
A study recently initiated by the Agency for Healthcare Research and Quality will develop a distributed network prototype by aggregating medical records and claims data for diabetes and hypertension therapy
Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market